New Therapies

Expanding treatment options and ongoing challenges for urologic cancers


 

Urologic cancers are those that form in organs of the urinary and male reproductive systems, the most significant among them being cancers of the bladder, kidney, prostate, and testicles. Collectively, they are diagnosed in close to 400,000 Americans each year and are responsible for almost 60,000 deaths annually. 1 Here, we describe the most recent developments in treating these malignancies.

Update/related article
Atezolizumab approval marks first new treatment option for bladder cancer in more than 3 decades

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Prostate cancer recurrence rates low with SBRT
MDedge Hematology and Oncology
Hypofractionated RT safe, convenient in low-risk prostate cancer
MDedge Hematology and Oncology
In favorable intermediate-risk prostate cancer, brachytherapy alone suffices
MDedge Hematology and Oncology
Adjuvant sunitinib offers DFS edge in high-risk RCC
MDedge Hematology and Oncology
Cabozantinib used as first-line therapy prolongs PFS for metastatic RCC
MDedge Hematology and Oncology
ADT may increase dementia risk in prostate CA
MDedge Hematology and Oncology
Cancer survivors report two times greater medication use for anxiety and depression
MDedge Hematology and Oncology
Targeting HER1/2 falls flat in bladder cancer trial
MDedge Hematology and Oncology
Cabozantinib bests sunitinib against metastatic RCC
MDedge Hematology and Oncology
Renal cell carcinoma approval adds another notch to cabozantinib’s belt
MDedge Hematology and Oncology